ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:

American College of Allergy, Asthma, & Immunology’s Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation:

  • Poster: Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study
    Speaker: John Anderson, M.D.
    Format: e-Poster (R102)
    Date, Time: Friday, Oct. 25, 2:00-2:15 p.m. EDT
    Location: Monitor 21, Exhibit Hall A
  • Poster: Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results
    Speaker: John Anderson, M.D.
    Format: e-Poster (R103)
    Date, Time: Friday, Oct. 25, 2:15-2:30 p.m. EDT
    Location: Monitor 21, Exhibit Hall A
  • Poster: Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders
    Speaker: Evangelia Pardali, Ph.D.
    Format: e-Poster (R088)
    Date, Time: Friday, Oct. 25, 2:30-2:45 p.m. EDT
    Location: Monitor 20, Exhibit Hall A
  • Poster: Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders
    Speaker: Evangelia Pardali, Ph.D.
    Format: e-Poster (R090)
    Date, Time: Friday, Oct. 25, 3:00-3:15 p.m. EDT
    Location: Monitor 20, Exhibit Hall A
  • Poster: The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans
    Speaker: Juan Bravo, Ph.D.
    Format: e-Poster (R112)
    Date, Time: Friday, Oct. 25, 4:30-4:45 p.m. EDT
    Location: Monitor 21, Exhibit Hall A
  • Poster: CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis
    Speaker: H. James Wedner, M.D.
    Format: e-Poster (R100)
    Date, time: Friday, Oct. 25, 5:30-5:45 p.m. EDT
    Location: Monitor 20, Exhibit Hall A
  • Poster: Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life
    Speaker: H. James Wedner, M.D.
    Format: e-Poster (R101)
    Date, Time: Friday, Oct. 25, 5:45-6:00 p.m. EDT
    Location: Monitor 20, Exhibit Hall A

Canadian Society of Allergy and Clinical Immunology (CSACI), Banff, Alberta, Canada, November 6-9, 2024. Three abstracts have been accepted for poster presentation.

  • Poster: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 Trial
    Speaker: William H. Yang, M.D., FRCPC, FAAAAI
    Format: Poster
    Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
  • Poster: Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results
    Speaker: William H. Yang, M.D., FRCPC, FAAAAI
    Format: Poster
    Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
  • Poster: Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results 
    Speaker: Hugo Chapdelaine, M.D., FRCPC
    Format: Poster
    Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)

Japanese Society of Allergology (JSA), Kyoto, Japan, October 18-20, 2024. One abstract has been accepted for oral presentation.

  • Presentation: Efficacy and safety of oral deucrictibant IR capsule in HAE: RAPIDe-3 phase 3 trial design
    Speaker: Prof. Michihiro Hide, M.D., Ph.D.
    Format: Oral Presentation
    Date, Time: Sunday, Oct. 20, 13:30-14:45 JST (12:30 -1:45 a.m. EDT)

The presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of bradykinin-mediated angioedema effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both prophylactically and on-demand. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks in the coming months. For more information, visit https://pharvaris.com/.


Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.